Literature DB >> 9011444

The presence of Helicobacter pylori in nonoperated duodenal ulcer patients compared to patients late after highly selective vagotomy.

A Csendes1, G Smok, M Coronel, R Avendaño, G Zenteno, H Cordova.   

Abstract

There are many recent studies that clearly suggest that Helicobacter pylori (HP) is an etiological agent for duodenal ulcer disease (1-3). Randomized trials have shown that duodenal ulcers treated by omeprazole or H2 blockers heal faster if HP is eradicated concurrently (4-6). Besides, several studies have demonstrated that eradication of HP significantly reduces duodenal ulcer relapses (7-9). Patients followed up to 7 years after eradication of HP demonstrated that 92% remained HP negative, with only 3% recurrence (10). Highly selective vagotomy has been the treatment of choice for duodenal ulcer patients who are candidates for surgical therapy (11, 12). The late results have shown an approximately 10% recurrence rate 8 to 10 years after surgery (13, 14). We hypothesized that in these asymptomatic cases after HSV, HP probably will exist in a minor proportion of cases, similar to what happens after successful medical antiulcer therapy. Therefore the purpose of the present study was to determine the HP status at the antrum in a group of nonoperated duodenal ulcer patients compared to a group submitted to highly selective vagotomy many years prior to the actual study.

Entities:  

Mesh:

Year:  1996        PMID: 9011444     DOI: 10.1007/bf02100129

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  9 in total

1.  Eradication of Helicobacter pylori reduces gastric and duodenal ulcer recurrence.

Authors:  L Laine
Journal:  Gastroenterology       Date:  1992-11       Impact factor: 22.682

Review 2.  Helicobacter pylori and peptic ulcers: the present position.

Authors:  S Moss; J Calam
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

Review 3.  Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease.

Authors:  D Y Graham
Journal:  J Gastroenterol Hepatol       Date:  1991 Mar-Apr       Impact factor: 4.029

Review 4.  Helicobacter pylori: current status.

Authors:  D Y Graham; M F Go
Journal:  Gastroenterology       Date:  1993-07       Impact factor: 22.682

5.  One-year follow-up of duodenal ulcers after 1-wk triple therapy for Helicobacter pylori.

Authors:  J J Sung; S C Chung; T K Ling; M Y Yung; A F Cheng; S W Hosking; A K Li
Journal:  Am J Gastroenterol       Date:  1994-02       Impact factor: 10.864

6.  Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study.

Authors:  J Labenz; E Gyenes; G H Rühl; G Börsch
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

Review 7.  Eradication of Helicobacter pylori: therapies and clinical implications.

Authors:  H J O'Connor
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

8.  Cure of duodenal ulcer associated with eradication of Helicobacter pylori.

Authors:  E A Rauws; G N Tytgat
Journal:  Lancet       Date:  1990-05-26       Impact factor: 79.321

9.  The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence--a 24 month follow-up study.

Authors:  N Y Kim; H S Oh; M H Jung; S H Wee; J H Choi; K H Lee
Journal:  Korean J Intern Med       Date:  1994-07       Impact factor: 2.884

  9 in total
  1 in total

Review 1.  Evaluation and management of patients with recurrent peptic ulcer disease after acid-reducing operations: a systematic review.

Authors:  Richard H Turnage; George Sarosi; Byron Cryer; Stuart Spechler; Walter Peterson; Mark Feldman
Journal:  J Gastrointest Surg       Date:  2003 Jul-Aug       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.